BCL-2 was overexpressed in 72 of 93 cases (77.4%), whereas 21 of 93 samples (22.6%) showed no or negligible expression (defined as absent or weak expression in ≤20% of AML blasts). This evidence concerns the gene BCL2 and acute myeloid leukemia.